IL157701A0 - N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same - Google Patents

N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

Info

Publication number
IL157701A0
IL157701A0 IL15770102A IL15770102A IL157701A0 IL 157701 A0 IL157701 A0 IL 157701A0 IL 15770102 A IL15770102 A IL 15770102A IL 15770102 A IL15770102 A IL 15770102A IL 157701 A0 IL157701 A0 IL 157701A0
Authority
IL
Israel
Prior art keywords
compound
methyl
processes
producing
active ingredient
Prior art date
Application number
IL15770102A
Other languages
English (en)
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL157701A0 publication Critical patent/IL157701A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
IL15770102A 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same IL157701A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (fr) 2001-03-12 2002-03-11 Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production

Publications (1)

Publication Number Publication Date
IL157701A0 true IL157701A0 (en) 2004-03-28

Family

ID=27346214

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15770102A IL157701A0 (en) 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
IL157701A IL157701A (en) 2001-03-12 2003-09-02 N-compound - Phenylarylsulfonamide and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157701A IL157701A (en) 2001-03-12 2003-09-02 N-compound - Phenylarylsulfonamide and pharmaceutical preparations containing them

Country Status (24)

Country Link
US (3) US7235667B2 (ru)
EP (2) EP1369419B1 (ru)
JP (3) JP3555620B2 (ru)
KR (1) KR100886854B1 (ru)
CN (1) CN1294126C (ru)
AT (2) ATE522513T1 (ru)
AU (1) AU2002238855B2 (ru)
BR (1) BR0208027A (ru)
CA (1) CA2439604C (ru)
CZ (1) CZ304035B6 (ru)
DE (1) DE60220255T2 (ru)
DK (2) DK1369419T3 (ru)
ES (1) ES2286230T3 (ru)
HU (1) HU230056B1 (ru)
IL (2) IL157701A0 (ru)
MX (1) MXPA03008134A (ru)
NO (1) NO329682B1 (ru)
NZ (1) NZ528120A (ru)
PL (1) PL218750B1 (ru)
PT (2) PT1612208E (ru)
RU (1) RU2299202C2 (ru)
TW (1) TWI317359B (ru)
WO (1) WO2002072564A1 (ru)
ZA (1) ZA200306884B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004022549A1 (ja) * 2002-09-09 2005-12-22 小野薬品工業株式会社 4−メチル−1,3−チアゾール−2−イルスルホニルハライドの製造方法
JP5015586B2 (ja) * 2003-01-29 2012-08-29 アステランド ユーケイ リミテッド Ep4受容体アンタゴニスト
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
WO2005000356A1 (ja) * 2003-06-27 2005-01-06 Ono Pharmaceutical Co., Ltd. 尿路疾患治療剤
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JPWO2006004115A1 (ja) * 2004-07-05 2008-04-24 中外製薬株式会社 過活動膀胱治療剤
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
ES2437323T3 (es) * 2007-02-16 2014-01-10 Ono Pharmaceutical Co., Ltd. Agente terapéutico para trastornos de la micción
US8048898B2 (en) * 2007-08-01 2011-11-01 Taisho Pharmaceutical Co., Ltd Inhibitor of binding of S1P1
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2305641A4 (en) * 2008-06-23 2012-08-22 Astellas Pharma Inc SULPHONAMIDE COMPOUND OR SALT THEREOF
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
EP2598481B1 (en) 2010-07-26 2016-08-31 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
JP6103893B2 (ja) * 2012-11-15 2017-03-29 サントリー食品インターナショナル株式会社 コーヒーオイルの製造方法
CN106660063B (zh) * 2014-04-30 2019-06-18 佩纳尔维工业有限公司 用于将液体应用于不同形状的盖子上的可编程同心头
EP3375782B1 (en) * 2015-11-13 2020-07-29 Daewoong Pharmaceutical Co., Ltd. Sodium channel blocker
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
JPS5748534B2 (ru) * 1974-03-04 1982-10-16
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) * 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
AU4431400A (en) * 1999-05-12 2000-12-05 Japan As Represented By President Of National Cancer Center Anticancer agents containing ep1 antagonists as the active ingredient
EP1201238A4 (en) 1999-07-29 2003-01-15 Ono Pharmaceutical Co SULPHONAMIDE DERIVATIVES AND HEALING AGENTS FOR ALLODYNIA
EP1369129A4 (en) 2001-03-14 2005-08-03 Ono Pharmaceutical Co ANTIDEPRESSOR REMEDIES CONTAINING AN EP1 ANTAGONIST AS ACTIVE INGREDIENT

Also Published As

Publication number Publication date
JP3741120B2 (ja) 2006-02-01
US20060030713A1 (en) 2006-02-09
ATE522513T1 (de) 2011-09-15
HU230056B1 (hu) 2015-06-29
US8088802B2 (en) 2012-01-03
ATE362924T1 (de) 2007-06-15
CZ304035B6 (cs) 2013-08-28
US7629369B2 (en) 2009-12-08
DK1369419T3 (da) 2007-09-24
ZA200306884B (en) 2005-03-30
PT1612208E (pt) 2011-10-12
NO329682B1 (no) 2010-11-29
NO20034007D0 (no) 2003-09-10
EP1369419A1 (en) 2003-12-10
NZ528120A (en) 2006-05-26
PL218750B1 (pl) 2015-01-30
IL157701A (en) 2010-06-30
RU2299202C2 (ru) 2007-05-20
CN1509278A (zh) 2004-06-30
PL365100A1 (en) 2004-12-27
JP2004149545A (ja) 2004-05-27
EP1369419B1 (en) 2007-05-23
JP3555620B2 (ja) 2004-08-18
KR100886854B1 (ko) 2009-03-05
DK1612208T3 (da) 2011-12-12
BR0208027A (pt) 2004-12-28
CZ20032452A3 (cs) 2003-11-12
HUP0400155A2 (hu) 2004-08-30
PT1369419E (pt) 2007-08-16
CA2439604C (en) 2012-05-01
HUP0400155A3 (en) 2007-05-02
JPWO2002072564A1 (ja) 2004-07-02
US20100041708A1 (en) 2010-02-18
TWI317359B (en) 2009-11-21
WO2002072564A1 (fr) 2002-09-19
KR20030082978A (ko) 2003-10-23
EP1612208A3 (en) 2006-12-06
EP1369419A4 (en) 2005-03-16
US7235667B2 (en) 2007-06-26
AU2002238855B2 (en) 2007-12-06
EP1612208B1 (en) 2011-08-31
CN1294126C (zh) 2007-01-10
RU2003127677A (ru) 2005-03-27
EP1612208A2 (en) 2006-01-04
NO20034007L (no) 2003-11-12
DE60220255D1 (de) 2007-07-05
DE60220255T2 (de) 2008-01-17
JP4432051B2 (ja) 2010-03-17
MXPA03008134A (es) 2004-03-10
JP2006028193A (ja) 2006-02-02
CA2439604A1 (en) 2002-09-19
ES2286230T3 (es) 2007-12-01
US20050124672A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
IL157701A0 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
NZ514661A (en) alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
DE60018064D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
NO20032510D0 (no) Organiske forbindelser
JP2003501361A5 (ru)
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
ATE404211T1 (de) Xenon als nmda-antogonist zur neuroprotektion
CA2518971A1 (en) Composition for administration of iron for the treatment of restless legs syndrome
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
EP1348698A4 (en) SUBSTITUTED CARBOXYLENE DERIVATIVES
NO20023551L (no) Ibuprofen-inneholdende aktivt middel-preparat
WO2003008365A3 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
ZA993528B (en) A compound for use in treating glaucoma and ischemic retinopathy.
EP1172106A3 (en) Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
WO2002056870A3 (en) Method for treating sleep disorders